All In Biotech

Drug Trial Radar · NCT06950385

Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis

A Phase 3, Multi-Site, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of eRapa to Improve Clinical Outcomes in Patients With Familial Adenomatous Polyposis

Last checked: Nov 19, 2026Latest source record: Jun 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 168 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

168

Planned (sponsor's estimate)

Start

Jul 18, 2025

Primary completion

Jul 2030

Study completion Jan 2031

Sponsor

Lead sponsor
Rapamycin Holdings Inc.Industry
Sponsor type
Industry
Collaborators
Biodexa Pharmaceuticals
First posted
Apr 30, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main goal of this clinical trial is to learn if the drug eRapa works to slow down the progression of disease in patients diagnosed with Familial Adenomatous Polyposis (FAP). Researchers will compare eRapa to Placebo. The questions to be answered by this trial are: * Does taking eRapa help to slow down the progression of the disease in patients with FAP? * Is eRapa a safe treatment for patients diagnosed with FAP? * What is the effect of eRapa on the number of polyps found in GI tract of patients diagnosed with FAP? * How does treatment with eRapa affect a patient's quality of life? Participants will: * Take eRapa or placebo once per day every other week until disease progresses (gets worse), stops taking part in the trial or dies. * Visit the clinic once every 3 months for check ups and tests. * Have an endoscopy at the start of the trial and then every 6 months to check on whether the disease is getting better or worse.

Conditions

  • Familial Adenomatous Polyposis (FAP)

Interventions

  • eRapa (encapsulated rapamycin)Drug

    0.5 mg capsules for oral use; white opaque capsule filled with off-white powder; Trial intervention will be provided in 28-count round high-density polyethylene bottles with a polypropylene child-resistant screw cap and foil induction seal.

  • PlaceboDrug

    Capsules in 28-count round high-density polyethylene bottles with a polypropylene child-resistant screw cap and foil induction seal.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS) in high-risk patients with FAP treated with eRapa versus placebo.Time frame: 3 years

Locations

29 sites in 7 countries. Site status is shown where the registry gives one.

  • City of Hope

    Arcadia, California · Recruiting

  • Yale Cancer Center

    New Haven, Connecticut · Recruiting

  • Georgetown University

    Washington D.C., District of Columbia · Recruiting

  • Digestive & Liver Center of Florida

    Orlando, Florida · Recruiting

  • Cleveland Clinic Florida

    Weston, Florida · Recruiting

  • University of Chicago

    Chicago, Illinois · Recruiting

  • University of Kansas Medical Center

    Kansas City, Kansas · Recruiting

  • Johns Hopkins University

    Baltimore, Maryland · Recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • University of Michigan

    Ann Arbor, Michigan · Recruiting

  • Department of Surgery, Section of Colon Rectal and Surgery

    St Louis, Missouri · Recruiting

  • Cleveland Clinic

    Cleveland, Ohio · Recruiting

  • Ohio State University

    Columbus, Ohio · Recruiting

  • Geisinger Medical Center

    Danville, Pennsylvania · Recruiting

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania · Recruiting

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Benaroya Research Institute at Virginia Mason

    Seattle, Washington · Recruiting

  • University of Washington - Fred Hutchinson

    Seattle, Washington · Recruiting

  • Copenhagen University Hospital

    Copenhagen, Denmark · Recruiting

  • Universitätsklinikum Bonn

    Bonn, Germany · Recruiting

  • IRCCS Ospedale San Raffaele

    Milan, Italy · Recruiting

  • Istituto Nazionale dei Tumori

    Milan, Italy · Recruiting

  • Amsterdam UMC

    Amsterdam, Netherlands · Recruiting

  • Radboud University Medical Center

    Nijmegen, Netherlands · Recruiting

  • Hospital Oncologico - Puerto Rico Medical Center

    Rio Piedras, Puerto Rico · Recruiting

  • Hospital Clínic de Barcelona

    Barcelona, Spain · Recruiting

  • Hospital Comarcal de Inca

    Inca, Spain · Recruiting

  • Hospital General Universitario Gregorio Marañón

    Madrid, Spain · Recruiting

  • Hospital La Fe de Valencia

    Valencia, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.